Immediate steps for patients: Stop taking tirzepatide immediately and do not administer any further doses until medically reviewed Seek urgent medical attention by contacting NHS 111, attending an emergency department, or calling 999 if symptoms are severe Avoid eating or drinking if experiencing severe pain or vomiting until medically assessed Avoid alcohol completely if this is a contributing factor Clinical assessment and investigation: When patients present with suspected pancreatitis, healthcare professionals should conduct a thorough evaluation including: Detailed history : Characterisation of pain, associated symptoms, medication history (including tirzepatide dose and duration), alcohol intake, and previous pancreatic disease Physical examination : Assessment for epigastric tenderness, abdominal guarding, fever, tachycardia, and signs of systemic compromise Laboratory investigations : Serum lipase (preferred in UK practice for specificity) or amylase, full blood count, renal function, liver function tests, calcium, glucose, and lipid profile Imaging studies : Abdominal ultrasound to identify gallstones
For example, if you normally inject on Wednesdays but need to switch to Mondays, inject on Monday, then continue every Monday
Test one product for 4 weeks, track appetite changes, and add another only if you still need support
What If Your Side Effects Dont Improve
Genetic and Biomarker Factors That Inform Treatment Suitability Your genetic predispositions in GLP-1 receptor (GLP1R rs6923761), GIP receptor (GIPR rs1800437), and metabolic genes (FTO rs9939609, MC4R rs17782313) may influence how your body responds to tirzepatide
this is usually reversible if detected early (Alashry and Morsy, 2021)
